A major Swiss skincare manufacturer reported impressive financial results Thursday, announcing that quarterly revenue climbed 25.5% to reach $1.47 billion when adjusted for currency fluctuations.
Galderma, headquartered in Zug, Switzerland, credited robust American consumer demand for driving the strong performance during the first three months of 2024. The company’s U.S. sales surged an impressive 41.5% compared to the same period last year.
“Based on the strong start to the year, the guidance is increasingly being de-risked with confidence to navigate a volatile environment,” Galderma said in a statement.
The skincare specialist, which began trading on Swiss stock markets slightly more than two years ago, indicated it expects any potential impact from U.S. trade tariffs to remain “manageable” throughout this year.
The company’s annual projections already account for possible tariff effects on its popular Sculptra and Restylane injectable products, as well as anticipated consequences from recent U.S. policy announcements regarding pharmaceutical and pharmaceutical ingredient imports.
